MYNZ MAINZ BIOMED BV

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023

Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 

BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, joins advocacy organizations around the world in recognizing Colorectal Cancer Awareness Month in March. Colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases in 2020. This year, Mainz Biomed will be hosting several educational and training events throughout Germany to raise awareness of the importance of early detection.

“We have developed these events to support the colorectal cancer community, as this disease is the third most common cancer globally and the fourth leading cause of cancer death in the US,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our goal is to reduce these statistics and save lives by raising awareness about the simplicity and efficacy of using at-home CRC detection kits, like ColoAlert. Our non-invasive DNA stool test allows people to screen themselves in the comfort of their own home and then receive a follow-up notification from their physician to discuss results and next steps.”

Upcoming Colorectal Cancer Awareness Month Events

Professionals

Training Sessions for gastroenterologists, healthcare providers

Gastro-Update Conference;

#1 Friday and Saturday, March 10-11, 2023 (Time TBD)

Rheingoldhalle; Mainz

#2 Friday and Saturday, March 24-25, 2023 (Time TBD)

Berlin Congress Center; Berlin/

Public

Educational Event for patients, families, caregivers, advocates

Saturday, March 11, 2023 (09:00-16:00)

(Outdoor event venue TBD); Mainz Altstadt

Mainz Biomed invites others to further amplify awareness of CRC by using the #BlueForCRC and #CRCAwareness hashtags on social media and “going blue” on Friday, March 3 by dressing in blue!

For media inquiries, please contact In Europe:

MC Services AG

Anne Hennecke/Caroline Bergmann

20





In the US:

Spectrum Science

Melissa Laverty/Valerie Enes



For investor inquiries, please contact 



EN
01/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MAINZ BIOMED BV

 PRESS RELEASE

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert® BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal cancer (CRC) screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. In Switzerland, CRC screening programs pr...

 PRESS RELEASE

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of O...

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares for gross proceeds of approximately $3.0 m...

 PRESS RELEASE

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Co...

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a diagnostics company specializing in the early detection of cancer, today announced a collaboration with CARE diagnostica Laborreagenzien GmbH (“CARE”). CARE is currently working with more than 15 statutory health insurance ...

 PRESS RELEASE

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextG...

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition Company Advances its Progress toward FDA Premarket Approval Study for its Next Generation Colorectal Cancer Screening Product and Makes a Strategic Acquisition in the Field of Pancreatic Cancer Screening BERKELEY, Calif. and MAINZ, Germany, July 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, toda...

 PRESS RELEASE

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic C...

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank of the German federal state of Rheinland-Pfalz. Under the ISB’s Innovation and Technology Support Program ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch